Getinge AB Due Diligence

Run due diligence on Getinge AB: check compliance and get alerts when suppliers or ownership change.

Sweden · owned by Independent (Sweden) · getinge.com · 15 vendors

Getinge AB is a leading global medical technology company that provides products, solutions, and services for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, digital health, pharmaceutical production, and laboratory research. The company serves healthcare professionals, hospitals, and life science organizations worldwide with the mission of saving lives and improving patient outcomes. Getinge is publicly listed and headquartered in Gothenburg, Sweden, with operations spanning multiple continents.

Resilience scores

Technology vendors

Insights

Last updated 2026-10-06 · revision 3

15 direct vendors, 234 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Migration Readiness: 7/10

Assessed by AI based on technology stack characteristics (cloud-native vs legacy, containerization, microservices), regulatory environment, data residency requirements, financial stability, and vendor lock-in risks. The score ranges from 0-10, where higher scores indicate better readiness for technology migration.

Getinge AB exhibits a good level of migration readiness, primarily driven by its modern internal tech stack. The adoption of Microsoft Azure, Docker, and Kubernetes provides a strong foundation for cloud-native migration and modernization efforts. The explicitly stated 'Low' vendor lock-in risk, attributed to a diverse vendor base (15 vendors), offers considerable flexibility in selecting new platforms and services without being heavily constrained by existing contracts or proprietary technologies. Consistent revenue growth suggests the financial capacity to invest in significant migration initiatives. However, the highly regulated environment (GDPR, HIPAA, ISO 13485, MDR, FDA, NIS2) and stringent data residency requirements (EU, USA, and other local requirements) present significant challenges. Migrating sensitive healthcare data while maintaining compliance across multiple jurisdictions will necessitate meticulous planning, robust security measures, and potentially complex hybrid or multi-cloud architectures, which could increase the cost and duration of migration efforts. While much of the tech stack is modern, the presence of SAP ERP indicates some legacy components that may require specific strategies (e.g., re-platforming or re-factoring) rather than a straightforward lift-and-shift approach.

Compliance

12 in-scope frameworks identified; showing 3.

HIPAA (source) — No public evidence

Getinge operates extensively in the US healthcare market. If its products or services involve the handling of Protected Health Information (PHI) on behalf of covered entities, it would be subject to HIPAA as a Business Associate.

Evidence: https://www.fiercebiotech.com/medtech/getinge-life-support-systems-temporarily-lose-ce-marks-due-issues-sterile-packaging

US FDA Medical Device Regulations — Evidence found

Getinge manufactures and sells medical devices in the United States, making it subject to the FDA's Quality System Regulation (21 CFR Part 820).

Evidence: https://www.getinge.com/us/company/sustainability/responsible/, https://bebee.com/us/jobs/risk-management-engineer-quality-defined-term-getinge-ab--lensa-2365_e560f34bc82a57655c8af3a33100fd55cfde797428a91adb4eea64e6fca22192, https://www.monster.com/job-openings/sr-engineer-process-development-wayne-nj-wayne-nj--54439a5a-5bb1-4a55-975b-e467b8f645b1, https://unblock.federalregister.gov/, https://www.getinge.com/us/company/news/press-releases/2022/4404539-U.S.-Food-and-Drug-Administration-broadens-the-consent, https://www.getinge.com/us/company/news/press-releases/2019/3198703-Datascope-a-subsidiary-of-Getinge-receives-a-warning/

China NMPA Regulations — No public evidence

Getinge has a significant presence in China, including manufacturing facilities and a dedicated Chinese website, making its medical devices subject to regulation by the National Medical Products Administration (NMPA).

Evidence: https://www.thestandard.com.hk/news/article/211088/Surgical-light-manufacturer-Getinge-banned-from-tendering-for-new-contracts-Hospital-Authority, https://en.wikipedia.org/wiki/Getinge_Group, https://www.getinge.com/us/company/, https://www.regdesk.co/blog/chinas-nmpa-releases-39-updated-medical-device-registration-guidelines/, https://www.emergobyul.com/sites/default/files/2024-12/China-NMPA-Registration-Whitepaper.pdf, https://cisema.com/blog/china-medical-device-risk-classification-guide

Financials

Three-year financials

Financial Resilience Score: 7/10

Getinge demonstrates solid financial resilience supported by a robust balance sheet with an equity/assets ratio of 52.2%, net debt/equity of 0.33, and leverage of 1.5x adjusted EBITDA. Net interest-bearing debt declined to SEK 9,840M in 2025 from SEK 10,467M in 2024, and the company maintains significant liquidity with SEK 6,075M in unused committed credit facilities plus an EUR 470M syndicated revolver maturing in 2030. Cash generation remains strong with operating cash flow of SEK 3,949M and free cash flow of SEK 2,652M in 2025. Revenue quality is a key strength: approximately 66% of 2025 net sales (SEK 23,001M) come from recurring revenue streams (consumables, service, and spare parts), providing predictability and resilience through economic cycles. The company's diversification across three business areas and over 135 countries, plus the long-term stability provided by controlling shareholder Carl Bennet AB (50.19% of votes), further supports resilience. However, resilience is constrained by notable headwinds including tariff and FX impacts exceeding SEK 1 billion in 2025, ongoing FDA Consent Decree remediation across multiple sites, legal exposures in Brazil, product recalls (Cardiosave), and heavy goodwill concentration (SEK 25,775M, or 46% of total assets) that creates impairment risk. The adjusted EBITA margin held flat at 14.0% despite these pressures, suggesting operational resilience but limited near-term margin expansion.

Key strengths: Strong balance sheet: equity/assets ratio 52.2%, net debt/equity 0.33, leverage 1.5x adjusted EBITDA, Recurring revenue represents ~66% of net sales (SEK 23,001M), Robust liquidity with SEK 6,075M unused credit facilities plus EUR 470M revolver, Strong cash flow generation: SEK 3,949M operating cash flow, SEK 2,652M free cash flow in 2025, Geographic diversification across 135+ countries, Long-term controlling shareholder (Carl Bennet AB) providing stability, Dividend increased to SEK 4.75/share (from SEK 4.60)

Risk factors: Tariff and FX headwinds exceeding SEK 1 billion in 2025, FDA Consent Decree remediation across multiple US and German sites, Brazil CGU anti-competitive investigation (SEK 482M provision), Cardiosave intra-aortic balloon pump CE mark issues and field actions, Goodwill concentration: SEK 25,775M (46% of total assets) creates impairment risk, Restructuring costs of SEK 374M in 2025 tied to Surgical Perfusion phase-out, High US market exposure (40.5% of sales) amid tariff environment

Revenue by geography

Revenue by product/service

Workforce by country

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report